Bactiguard Holding AB (publ) (BACTI_B) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bactiguard Holding Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.503 -- 00:00:04.988 Thank you, Operator, and welcome to the presentation of Back to Guard's report for the 00:00:04.988 -- 00:00:08.131 second quarter 2025. Our CFO, 00:00:08.131 -- 00:00:12.456 Patrick Buck, and I will go through the presentation together, and we will have a Q&A 00:00:12.456 -- 00:00:15.457 session towards the end. 00:00:19.923 -- 00:00:23.888 As usual, I would like to share some highlights from the past quarter, and Patrick will 00:00:23.888 -- 00:00:27.892 go through the figures in more detail later in the presentation. 00:00:27.892 -- 00:00:33.622 First, we continue to deliver EBITDA profitability with this quarter totaling 4.4 00:00:33.622 -- 00:00:39.071 million SEC. This is the fifth consecutive quarter with positive EBITDA for BactaGard 00:00:39.071 -- 00:00:44.597 in alignment with our promise to our investors during our strategic transformation. 00:00:44.817 -- 00:00:48.640 Revenues for Q2 came in at 52.1 00:00:49.624 -- 00:00:54.852 million SEC, which was a decrease of 14.4% compared to last year. 00:00:54.852 -- 00:00:59.459 This is mainly explained by lower revenues from the BD partnership due to longer than 00:00:59.459 -- 00:01:04.747 expected timelines for new market registrations, as well as negative US dollar 00:01:04.747 -- 00:01:09.835 currency impact. Nevertheless, our collaboration with BD remains 00:01:09.835 -- 00:01:14.459 solid, and I will elaborate on this later in the presentation. 00:01:14.500 -- 00:01:19.766 We have also initiated early feasibility work relevant to cardiology under material 00:01:19.766 -- 00:01:25.032 transfer agreement. Cardiology is one of our newer key strategic therapeutic areas 00:01:25.032 -- 00:01:30.118 announced in the first quarter, and the applications for future potential lic...